Global Clinical Mass Spectrometry Market To Receive Overwhelming Hike In Revenues By 2026 With Top Key Players Agilent Technologies , Waters, Shimadzu Corporation, Danaher, PerkinElmer Inc., Thermo Fisher Scientific Inc.

Clinical mass spectrometry plays a vital role in the drug discovery pipeline for the development of personalized medicines. It is further used for live imaging of biological tissue samples for detection of biomarkers. Cost reduction and improved assay quality has driven the adoption of mass spectrometry. The American Association for Clinical Chemistry (AACC), states that the greater specificity of liquid chromatography–mass spectrometry-(LC MS) enables the measuring of testosterone for patients with low endogenous concentrations. This technique is more reliable than traditional immunoassays, especially for women and children. This led to the early adoption of the most recent generation of instruments using an established technology in the laboratories.

Request Customization of This Report @ https://www.coherentmarketinsights.com/insight/request-customization/193

Market Dynamics

Clinical mass spectrometry offers significant advantages related to clinical research and forensic toxicology applications in terms of speed, robustness, simplicity, and selectivity of small molecules. Clinical mass spectrometry manufacturers are continuously collaborating with clinical diagnostic companies to retain the market share for new products that can quantify low trace levels of disease biomarkers. In Cambridge (U.S.) Thermo Fisher is advancing proteomics and clinical translational research through collaborations at the Biomarkers Research Initiatives in mass spectrometry center. Furthermore, increasing demand for clinical mass spectrometry to perform diagnostic assays in the field of endocrinology, toxicology, leukemia, and biochemical genetics, which helps overcome limitations of conventional immunoassays is also expected to create a favorable environment for growth of the market over the forecast period.

Increasing Demand For Automation In Diagnostic Techniques To Drive Growth Of The Clinical Mass Spectrometry Market

Mass spectrometry enables various diagnostic analyses and study of functional genomics, metabolomics, and proteomics that facilitate development of a cost-effective analytic platform for analysis of samples. The automated laboratory systems provide several high-end functionalities such as MassEXTEND primer extension and nano liter dispensing of samples on to the spectroCHIPS, and data analysis using pre-loaded workstations that make the task of the clinicians and testing personnel easy and less tedious. Ease of management, quick results, and less complex functionality of these facilities are associated with low costs. Apart from cost- effectiveness, improved quality assays, simplicity, automation, and data reliability, increased sensitivity, reduced cross-reactivity & non-specific binding, and significantly low downtime are advantages offered by mass spectrometers over conventional immunoassays. Moreover, major capital investments associated with the set up and maintenance of these devices poses as a major restraint for the global market growth.

Competitive Landcape

Key companies covered as part of this study include Agilent Technologies , Waters, Shimadzu Corporation, Danaher, PerkinElmer Inc., Thermo Fisher Scientific Inc., Bruker, Mass Spectrometry Instruments (MSI), and Kore technology

The global clinical mass spectrometry market is estimated to be valued at US$ 4,982.5 million in 2017 and is expected to witness a CAGR of 7.3% over the forecast period (2017 – 2025).

Technological Advancements Leading To New Product Launch Is A Prominent Factor Fueling Growth Of The Clinical Mass Spectrometry Market

Advancements in technology includes miniaturization of mass spectrometry instruments and increasing automation of the entire spectrometric unit to reduce human efforts and improve efficiency of the instruments. The fully automated analyzer launched by Thermo Fisher in June 2017, is a step closer to achieve entirely automated systems in the mass spectrometry market that can be customized easily to be compatible with the laboratory information systems.

Ask For Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/193

North America held the maximum share of clinical mass spectrometry market in 2016, owing to the presence of major key players and strategic collaborations. The second largest market share is provided by Europe. Under the Federation of analytical Chemistry and Spectrometry Societies, American Society for Mass Spectrometry was formed in 1969, with over 7,500 scientists working together to make advancements in the clinical applications of mass spectrometry and allied topics in academic, industrial, and governmental laboratories. This in turn, creates a strong network of research base in North America thus, contributing to swift growth of the clinical mass spectrometry market. Asia Pacific is also expected to grow at a substantial rate due to increased investments in R&D by various players and government bodies along with the introduction of new in-house manufacturing and R&D facilities.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.